Literature DB >> 1889841

Renin release regulation during acute renin inhibition in normal volunteers.

J Ménard1, T T Guyene, G Chatellier, C H Kleinbloesem, P Bernadet.   

Abstract

Blockade of the renin-angiotensin system by an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (Ang II) antagonist is accompanied by a reactive rise in renin release. This rise is generally attributed to interruption of the short feedback loop between Ang II and renin release. Similarly, after the administration of a renin inhibitor, the plasma concentrations of active and total renin are increased and plasma renin activity is suppressed. The aim of the present study was to investigate if a fall in the plasma Ang II level is the unique determinant of the rise in the active renin (AR) level that follows renin inhibition. Six normal male volunteers participated in three successive 240-minute experiments at weekly intervals according to a single-blind randomized Latin square design. For experiment 1, Ang II was infused at 2 ng/kg/min from 0 to 60 minutes and at 4 ng/kg/min from 60 to 120 minutes. For experiment 2, 0.3 mg/kg of the new potent renin inhibitor Ro 42-5892 was injected at 30 minutes followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes. For experiment 3, Ang II and Ro 42-5892 were administered simultaneously at the same doses as described above. The mean +/- SEM Ang II concentration increased from 10.2 +/- 1.6 to 33.7 +/- 11.2 pg/ml after infusion of exogenous peptide. It decreased from 9.5 +/- 0.9 to 1.4 +/- 0.3 pg/ml after the injection of Ro 42-5892 and increased from 15.6 +/- 2.9 to 37.1 +/- 11.8 pg/ml after the simultaneous infusion of both compounds.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889841     DOI: 10.1161/01.hyp.18.3.257

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 2.  Angiotensin receptor blockers in diabetic nephropathy.

Authors:  D A Price; N K Hollenberg
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 3.  Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?

Authors:  Kunal Chaudhary; Ravi Nistala; Adam Whaley-Connell
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

Review 4.  Clinical pharmacokinetics and efficacy of renin inhibitors.

Authors:  G A Rongen; J W Lenders; P Smits; T Thien
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

5.  Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.

Authors:  C Weber; H Birnböck; J Leube; I Kobrin; C H Kleinbloesem; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

6.  Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration.

Authors:  Erika Costa de Alvarenga; Matheus de Castro Fonseca; Clarissa Coelho Carvalho; Rodrigo Machado Florentino; Andressa França; Eveline Matias; Paola Bianchi Guimarães; Carolina Batista; Valder Freire; Adriana Karaoglanovic Carmona; João Bosco Pesquero; Ana Maria de Paula; Giselle Foureaux; Maria de Fatima Leite
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

7.  Molecular basis of a redox switch: molecular dynamics simulations and surface plasmon resonance provide insight into reduced and oxidised angiotensinogen.

Authors:  Jennifer M Crowther; Letitia H Gilmour; Benjamin T Porebski; Sarah G Heath; Neil R Pattinson; Maurice C Owen; Rayleen Fredericks; Ashley M Buckle; Conan J Fee; Christoph Göbl; Renwick C J Dobson
Journal:  Biochem J       Date:  2021-09-17       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.